POCT D-dimer
[POCT D-dimer]
EPTIS factsheet 1177201 | Last revision 2024-09-24 | URL: https://www.eptis.bam.de/pts1177201 https://www.eptis.bam.de/pts1177201
| PT provider | ||||||||||
| PT provider | Weqas Weqas | |||||||||
| Based in | United Kingdom | |||||||||
| Language(s) | ||||||||||
| Remarks | D-dimer is a Fibrin Degradation Product (FDP) used to determine whether clot formation has occurred or not. Its clinical application is as part of the diagnosis pathway for venous thromboembolic diseases: Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). The diagnostic cut off is method dependent, however the majority of methods now report a cut off of ≥500 μg/L FEU for a positive D-dimer. Three samples are distributed bimonthly, with at least eighteen samples distributed annually. The panels consist of 6 endogenous pools, selected at D-dimer concentrations to cover negative, at or near the threshold and at a range of pathological concentrations. Each of the pools are distributed on 3 occasions over the year to assess both laboratory and method performance, including linearity, bias, within and between batch imprecision. Key Features: - Samples are supplied ready to use, no pre-analytical preparation is required. - Quantitative and Qualitative reporting available. - Programme assesses both laboratory and method performance, including bias, within and between batch imprecision and linearity. - Endogenous samples commutable across all testing platforms. - Panel covering the pathological range. - Scoring based on Milan Model 3 performance specification. For more information: https://www.weqas.com/services/poct-eqa/d-dimer/ or contact@weqas.com | |||||||||
| Keywords | ||||||||||
| Product groups |
Health care / medical devices
|
|||||||||
| Testing fields |
Medical analysis
|
|||||||||
| Technical details | ||||||||||
|
||||||||||
| Aims of the PT scheme | ||||||||||
| Target group of participants | Programme assesses both laboratory and method performance, including bias, within and between batch imprecision and linearity. | |||||||||
| Linked to specific legislation / standards | Accreditation by UKAS based on ISO/IEC 17043. | |||||||||
| Additional, subsidiary aims | validation of testing methods | |||||||||
| Number of participants | ||||||||||
| Accredited or otherwise reviewed by a 3rd party |
Accredited by UKAS on the basis of ISO/IEC 17043 for part of the parameters |
|||||||||
| Operation is commissioned / requested by | ||||||||||
| Fees and frequency | ||||||||||
| Participation fee | https://www.weqas.com/participantzone/subscription-charges/ | |||||||||
| Regularly operated | Yes (Frequency: Bimonthly. Samples: 3 x 1.0mL.) | |||||||||
| Year of first operation | 2011 | |||||||||
| Contact details of the PT provider | ||||||||||
| Provider | Contact person | |||||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Phone: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Phone: 44 (0) 29218 32884 Fax: Email: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
|||||||||
If you find any mistakes please contact the responsible EPTIS coordinator in United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.